non-viral-delivery
(2)
The $85 Million Bet That a DNA Scaffold Can Make Gene Therapy Re-Dosable
Code Biotherapeutics is trying to turn DNA into the FedEx network for genetic medicine. Its modular 3DNA scaffold promises bigger payloads, precise addresses and repeat delivery - but the public evidence is still preclinical.
CellFE
CellFE is an Alameda, California biotechnology company building microfluidics-based, non-viral cell-engineering instruments and consumables. Its Ryva mechanoporation platform squeezes cells through microfluidic channels to transiently open their membranes and deliver gene-editing payloads (mRNA, CRISPR-RNP, DNA vectors) in under 10 milliseconds, aiming to preserve cell health and viability where viral vectors and electroporation fall short. The goal is to make lifesaving cell therapies such as CAR-T faster, cheaper, and more scalable to manufacture.